GlassScriptPhysician profile
Cecelia T Madrid
NPI 1043363872
$5,724.61
in general payments reported to CMS, 2019-2025
38 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $1,042 · 2021: $2,656 · 2022: $454 · 2023: $215 · 2024: $75.97 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,318.16 | 2021 | |
| Abbvie INC. | $544.20 | 2019-2022 | |
| Novo Nordisk INC | $472.70 | 2019-2022 | |
| Lilly USA, LLC | $451.60 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $321.33 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.13 | 2019-2022 | |
| Philips North America LLC | $233.71 | 2019-2020 | |
| Topcon Healthcare Solutions, INC. | $231.87 | 2019-2020 | |
| Amgen INC. | $207.38 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $202.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $201.86 | 2019-2022 | |
| Glaxosmithkline, LLC. | $197.09 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Vertiflex, INC. | $116.01 | 2019 | |
| Melinta Therapeutics, LLC | $100.07 | 2019 | |
| Astellas Pharma US INC | $84.83 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $84.33 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $76.89 | 2025 | Gemtesa |
| Electromed, INC. | $50.89 | 2021-2022 | |
| Allergan, INC. | $48.38 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $46.49 | 2019 | |
| Horizon Therapeutics Plc | $45.73 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.91 | 2020-2021 | |
| Abbott Laboratories | $42.25 | 2021-2022 | |
| Biofire Diagnostics, LLC | $34.60 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.51 | 2021 | |
| Vanda Pharmaceuticals INC. | $25.68 | 2020 | |
| Radius Health, INC. | $25.67 | 2020 | |
| Eisai INC. | $24.13 | 2020 | |
| Alnylam Pharmaceuticals INC. | $24.02 | 2021 | |
| Nestle Healthcare Nutrition INC. | $23.67 | 2021 | |
| Sun Pharmaceutical Industries INC. | $22.52 | 2020 | |
| Alvogen INC | $21.70 | 2021 | |
| Antares Pharma, INC. | $18.88 | 2022 | |
| Medtronic USA, INC. | $16.30 | 2020 | |
| Zyla Life Sciences, INC. | $15.83 | 2019 | |
| Optinose US, INC. | $13.48 | 2019 | |
| Sk Life Science, INC. | $12.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecelia Madrid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.